Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

virin in combination with:

  • Janssen's non-nucleoside inhibitor TMC647055 and ritonavir in treatment-naïve genotype 1a and 1b HCV patients;
  • Gilead Sciences, Inc.'s nucleotide inhibitor sofosbuvir (GS-7977) in treatment-naïve and previous null-responder genotype 1 HCV patients; and
  • Bristol- Myers Squibb 's NS5A replication complex inhibitor daclatasvir in treatment-naive and previous null-responder genotype 1 HCV patients.

In addition, Janssen Pharmaceuticals, Inc. has entered into a non-exclusive collaboration with Vertex Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen of simeprevir and Vertex's investigational nucleotide analogue polymerase inhibitor VX-135 for the treatment of HCV. As a first step, Janssen Pharmaceuticals, Inc. is conducting a drug-drug interaction (DDI) study with simeprevir and VX-135. Janssen Pharmaceuticals, Inc. also has plans to initiate a Phase 2 trial of an investigational interferon-free regimen with simeprevir, TMC647055 and Idenix's IDX719, a once-daily, pan-genotypic NS5A inhibitor, with and without ribavirin.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure.

About Janssen R&D Ireland
At Janssen, we are dedicated to addres
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Hologic, Inc. (NASDAQ: HOLX ) announced today ... for the third quarter of fiscal 2015 on Wednesday, ... with the release, management will host a conference call ... Interested participants may listen to the call by dialing ... or 719-325-4804 (for international callers) and referencing access code ...
(Date:7/6/2015)... E-QURE Corp (OTCQB: EQUR), today announced that ... on July 9, 2015. DATE: Thursday, July 9, ... This will be a live, interactive online ... questions in real-time - both in the presentation hall ... attendees are not able to join the event live ...
(Date:7/6/2015)... and FARMINGTON, Conn. , ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of Series E warrants to purchase 21,917,808 ... warrants to purchase 2,191,781 shares of its common ...
Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), ... M.D., chief medical officer, is scheduled to present at the ... Wednesday, May 25, 2011 at noon BST. Dr. Patou is ... A live audio webcast of Pacira,s presentation can be ...
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... specializing in the development, manufacturing, and marketing of branded ... annual general meeting of shareholders (the "Meeting") will be ... Beijing time. The meeting will be held in No.699-18, ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference 2Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2
(Date:7/6/2015)... , ... July 06, 2015 , ... Health care systems ... ability of the medical field to access and use this “Big Data” to improve ... President and Chief Executive Officer of the Mount Sinai Health System in New York ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, ... to reduce their risk of having a fracture through the bone health screenings conducted ... Day. , “We are participating because our residents need this information to remain independent ...
(Date:7/6/2015)... Los Angeles, CA (PRWEB) , ... July 06, 2015 , ... ... now offering patients the opportunity to achieve their ideal appearance through comprehensive treatment solutions. ... discuss their goals with the doctor and receive a plan that resolves each of ...
(Date:7/6/2015)... ... July 06, 2015 , ... Orthopaedic & Spine ... 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took place on Tuesday, ... The procedure was an L5-S1 posterior lumbar interbody fusion on a 69 year ...
(Date:7/6/2015)... Texas (PRWEB) , ... July 06, 2015 , ... The ... thought-provoking look into the economic transformation associated with the U.S. economy over the past ... consequences associated with its use. In many ways, the book is a time capsule ...
Breaking Medicine News(10 mins):Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2
... Seed Oil for ... SEGUNDO, Calif., Feb. 25 When it comes ... antioxidant and cell,membrane benefits, not everything with pomegranate ... extract that counts! The Murad Vitalic(R) line with,Energizing ...
... Fla., Feb. 25 The Quantum Group,Inc. (Amex: ... that,Noel J. Guillama, President & CEO, will present ... on Thursday, February 28, 2008, which will,be held ... The presentations will be held in the ...
... New Haven, Conn. Erin Lavik , an ... was honored recently by the Connecticut Technology Council ... , The annual event, now in its fourth year, ... as small business owners, entrepreneurs, researchers, community leaders and ...
... Most Oscar pundits are obsessed,with red-carpet fashion, but Hollywood ... Academy Awards with a critic,s eye for,the best and ... smiles and simply,adequate smiles are really easy to notice ... Oscar party at The Oaks Center for Cosmetic,Dentistry., ...
... EZ-Access Patcom to Streamline Hospital,s Operations and Revenue ... ... Keane, Inc., a $1,billion-plus global services firm that specializes in enabling,transformation of ... a contract with Mount Sinai Hospital of Queens,part of New York-based Mount ...
... global warming by making people more aware of their ... Satellite Navigation Competition, sponsored by ESAs Technology Transfer Programme, ... , Concerned about global warming, many people are now ... dioxide (CO2). One option is to use public transport ...
Cached Medicine News:Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 3Health News:The Quantum Group to Present at the Jesup & Lamont Emerging Growth Stock Conference on February 28th 2Health News:The Quantum Group to Present at the Jesup & Lamont Emerging Growth Stock Conference on February 28th 3Health News:Yale scientist honored for academic innovation and leadership 2Health News:Keane Wins Revenue Cycle Management Implementation With Mount Sinai Hospital of Queens 2Health News:Keane Wins Revenue Cycle Management Implementation With Mount Sinai Hospital of Queens 3Health News:Tracking your carbon footprint 2Health News:Tracking your carbon footprint 3
... The Ulti-Mist™ HME product line has the ... pediatrics to adults and from intubated patients ... superior humidification for both anesthesia and critical ... HME/Filters provide maximum protection for patients and ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Ballard trach care HMES and filters, universal use, "Y" filter...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
Medicine Products: